Welcome to our dedicated page for Ispecimen SEC filings (Ticker: ISPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The iSpecimen Inc. (ISPC) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. iSpecimen’s filings offer detailed information about its online marketplace for human biospecimens, its capital structure, financing activities, governance, and interactions with The Nasdaq Capital Market. Stock Titan enhances these documents with AI-powered summaries designed to explain the key points of each filing in clear language.
For investors and analysts reviewing annual reports on Form 10-K and quarterly reports on Form 10-Q, iSpecimen’s disclosures describe its mission to accelerate life science research through a global biospecimen marketplace, its technology platform, and its classification as an emerging growth company and smaller reporting company. These periodic reports, when available, are central sources for understanding the company’s business model, risk factors, and operating environment.
Current reports on Form 8-K provide timely updates on material events. Recent 8-K filings include a November 21, 2025 report describing a Nasdaq notice that the company’s closing bid price had fallen below the $1.00 minimum required under Listing Rule 5550(a)(2), along with the timeframe provided to regain compliance. Other 8-Ks detail leadership changes, such as the appointment of a new Chief Executive Officer and the addition of an independent director, and report the results of a special meeting of stockholders where proposals related to a reverse stock split, an increase in authorized shares, private financing approvals, amendments to convertible securities, and an equity line of credit were approved.
Proxy statements on Schedule 14A (DEF 14A) shed light on corporate governance, director elections, stock incentive plans, and the agenda for annual and special meetings. The 2025 special meeting proxy statement outlines proposals to adjust the company’s capital structure and financing flexibility, while the 2025 annual meeting proxy statement covers director elections, auditor ratification, and a new stock incentive plan.
iSpecimen’s registration statements on Form S-1 and S-1/A describe offerings of common stock and pre-funded warrants, the use of proceeds, and detailed background on the company’s marketplace model. These filings also incorporate discussion of the company’s corporate treasury plan related to the Solana blockchain ecosystem and associated risk factors, as noted in the explanatory notes to recent amendments.
On Stock Titan, users can review these ISPC filings as they are updated in real time from EDGAR, while AI-generated overviews highlight important elements such as capital-raising terms, listing compliance matters, governance proposals, and structural changes to outstanding securities. This combination of source documents and AI explanations helps readers navigate complex forms, from 10-Ks and 10-Qs to 8-Ks, S-1 registration statements, and proxy materials, and track how iSpecimen manages its biospecimen marketplace business within the public-company regulatory framework.
iSpecimen Inc. is continuing efforts to complete its 2025 Annual Meeting of Stockholders. The meeting was first convened on December 31, 2025, but was repeatedly adjourned on January 23, 2026, February 13, 2026, March 13, 2026 and April 10, 2026 because a quorum was not present. The company now plans to reconvene the Annual Meeting on May 8, 2026 at 9:00 a.m. Eastern Time. The record date for stockholders entitled to vote remains November 3, 2025, and the proposals to be voted on are unchanged from those described in the definitive proxy statement filed on November 21, 2025.
iSpecimen Inc. filed an 8-K to share an operational update on its biospecimen logistics. The company has implemented a streamlined shipping model that sends human biospecimens directly from supplier sites to customers, avoiding prior central-hub routing that often added 7–14 days to delivery times.
Under the new approach, domestic shipments can arrive in as little as 1–2 days, a reduction of about 70–85% in transit time, while using fewer shipment handoffs to lower overall shipping costs. Internationally, iSpecimen has strengthened partnerships across Europe and Eastern Europe to expand access to rare biospecimens and support more consistent, timely deliveries.
The model is supported by enhanced training and operational alignment across the company’s global supplier network. Since implementation earlier in the year, customer feedback has reportedly been positive, with users citing faster, more reliable deliveries and improved overall experience.
iSpecimen Inc. operates a technology-driven marketplace that connects life science researchers with human biospecimens and associated data sourced from a global healthcare provider network. The iSpecimen Marketplace aggregates de-identified data from electronic health systems, enabling researchers to search, select, and procure specimens and custom collections through an integrated workflow from inquiry to invoice.
As of December 31, 2025, the platform incorporated approximately 19 million patient records, 105 million clinical specimen records, and 1.4 million banked specimen records, and had delivered over 218,000 specimens across more than 3,500 projects. The company is migrating from a legacy architecture to a cloud-native system built on its SalesStack solution to improve scalability, security, and workflow unification.
Financially, iSpecimen reported net losses of $10.5 million in 2025 and $12.5 million in 2024, with an accumulated deficit of $82.4 million and an explanatory going-concern paragraph in its audited financial statements. The workforce shrank from 24 employees at the end of 2024 to seven at the end of 2025. The company also disclosed a material weakness in internal control over financial reporting related to sales tax processes and is implementing remediation measures. Revenue and cost of revenue are concentrated among a small number of customers and suppliers, and the business depends heavily on expanding its supply network, data access, and marketplace capabilities in a highly regulated environment.
iSpecimen Inc. has been unable to complete its 2025 Annual Meeting of Stockholders because not enough shareholders have participated to reach a quorum. The meeting, originally convened on December 31, 2025 and reconvened on January 23, 2026, February 13, 2026, and March 13, 2026, was adjourned each time for this reason.
The company now plans to reconvene the Annual Meeting on April 10, 2026 at 9:00 a.m. Eastern Time. The record date remains November 3, 2025, and the proposals to be voted on are unchanged from those described in the definitive proxy statement filed on November 21, 2025.
iSpecimen Inc. reported that Siyun Yang resigned from its Board of Directors effective February 17, 2026. The company stated that her resignation was not due to any disagreement regarding operations, policies, or practices.
Ms. Yang had served as an independent director since February 2025 and sat on both the Audit Committee and the Nominating and Corporate Governance Committee. iSpecimen thanked her for her service and expressed well wishes for her future endeavors.
iSpecimen Inc. reported that its 2025 Annual Meeting of Stockholders, originally convened on December 31, 2025, has been repeatedly adjourned because not enough shares were represented to reach a quorum. The meeting was reconvened on January 23, 2026 and February 13, 2026, but a quorum was still not present.
The company now plans to reconvene the Annual Meeting on March 13, 2026 at 9:00 a.m. Eastern Time. Stockholders of record as of November 3, 2025 remain entitled to vote, and the proposals to be considered are unchanged from those described in the November 21, 2025 proxy statement.
iSpecimen Inc. filed a current report to share two operational updates. The company has completed Milestone 2 of its SalesStack digital transformation program, delivering a fully integrated, live production marketplace that connects customer requests with supplier inventories and supports core workflows like order processing and user management.
The new marketplace is live at mp.ispecimen.com and is designed to streamline operations, reduce costs, and support future growth through AI-assisted matching and legacy system sunset. Separately, iSpecimen highlighted recent performance of its site network, including rapidly procuring 500 influenza swab samples in a few weeks and consistently supplying cerebrospinal fluid for ongoing customer studies, alongside strong customer feedback on specimen quality and documentation.
iSpecimen Inc. is registering up to 101,000,000 shares of common stock for resale by existing investors. These shares are issuable upon conversion of Series C Convertible Non-Voting Preferred Stock that was sold in a December 2025 private placement for approximately $5.5 million of gross proceeds.
The company will not receive any proceeds from sales of these shares by the selling stockholders. After full conversion and completion of this offering, iSpecimen states there would be 110,771,046 shares of common stock outstanding. Its stock trades on the Nasdaq Capital Market under the symbol ISPC, and the company recently regained compliance with Nasdaq’s stockholders’ equity rules but remains below the $1.00 minimum bid requirement.